IFR US ECM Calendar
Week of February 23: AGT Food and Ingredients (Canada, food) ─ C$460m TSX IPO (Primary, Secondary). 15.33m-17.69m shares at C$26-$30. NBF, SCOT. TSX “AGTF”. OMERS is the selling shareholder.
February 25: Innovex International (US, oilfield services) ─ $152.4m ABB. 5.8m shares (Secondary) marketed at $25.50-$26.50 versus $29.25 last sale. JPM, CITI, JEFF, PS. Wall cross. Company currently buying the lesser of 10% or $15m of the shares being sold.
February 25: Lifestance Health (US, healthcare services) ─ $185.3m Block. 25m shares (Secondary) marketed at $7.04-$7.41 versus $7.41 last sale. JPM. Company concurrently buying back 7m shares on offering.
February 25: Larimar Therapeutics (US, biotech) ─ $75m ABB. Fixed size (Primary) marketed at $4.75-$5.25 versus $5.95 last sale. JPM, GUGG. Wall cross. Structured with pre-funded warrants.
February 25: Metropolitan Bank (US, regional bank) ─ $175m ABB. Fixed size (Primary) marketed at $83.00-$86.00 versus $93.85 last sale. UBS, HOVD. Wall cross.
February 25: Palvella Therapeutics (US, biotech) ─ $150m FO. Fixed size (Primary) versus $120.41 at launch. TDC, CANT, STFL, MIZU, LSCI, OPCO, CGEN, HCW. Reverse inquiry.
February 25: Vir Biotechnology (US, biotech) ─ $200m FO. Fixed size (Primary) versus $9.49 at launch. GS, LEER, GUGG, BARC.
February 26: Generate Biomedicines (US, biotech) ─ $425m IPO. 25m shares (Primary) at $15-$17. GS, MS, PS, GUGG, CANT. Nasdaq “GENB”.
February 26: LSI Industries (US, electrical components & equipment) ─ $75m FO. Fixed size (Primary) versus $22.47 at launch. OPCO, CHLM. Wall cross.
February 26: Ultra Clean (US, semiconductor equipment) ─ $400m 5y cvt marketed at 0% fixed, up 35%-40%. BARC, UBS. Capped call. Concurrent $40m share repurchase.
March 5: MiniMed (US, medical devices) - $784m IPO. 28m shares (Primary) at $25-$28. GS, BOFA, CITI, MS. Nasdaq “MMED”. Spin-off from Medtronic.
March 5: Robinhood Ventures Fund I (US, closed end fund) ─ $1bn IPO. 40m shares (Primary, Secondary) at $25.00. GS. Robinhood Markets is selling 5m shares. Marketing extended from scheduled 2/25 pricing.